CLINICAL_TRIALS
trial_result
· 2016-01-22
Clinical Trial Update: Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib [Phase 2]
Summary
A Phase 2 trial update reports results for dasatinib in advanced non-small cell lung cancer that progressed after Erlotinib or Gefitinib.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-01-22